ÄãºÃ£¬»¶Ó­À´µ½¾­¹ÜÖ®¼Ò [µÇ¼] [×¢²á]

ÉèΪÊ×Ò³ | ¾­¹ÜÖ®¼ÒÊ×Ò³ | Êղر¾Õ¾

Ò»ÖÖÐÂÐͺ£ÑóÀ´Ô´µÄÝì»·À໯ºÏÎïD19¿¹Ö×Áö»îÐÔ¼°»úÖÆÑо¿_ҩѧרҵ±ÏÒµÂÛÎÄ·¶ÎÄ

·¢²¼Ê±¼ä£º2014-12-09 À´Ô´£ºÈË´ó¾­¼ÃÂÛ̳
Ò»ÖÖÐÂÐͺ£ÑóÀ´Ô´µÄÝì»·À໯ºÏÎïD19¿¹Ö×Áö»îÐÔ¼°»úÖÆÑо¿_ҩѧרҵ±ÏÒµÂÛÎÄ·¶ÎÄ ¡¾ÕªÒª¡¿  Ä¿µÄ̽ÌÖÐÂÐͺ£ÑóÔ´ÐÔÝì»·À໯ºÏÎïD19µÄ¿¹Ö×Áö×÷Óü°·Ö×Ó»úÖÆ¡£·½·¨ ²ÉÓÃËļ׻ù¶þµªßòÀ¶(MTT)±ÈÉ«·¨¡¢ÍÑÑõºËÌǺËËáÄ©¶Ë×ªÒÆÃ¸½éµ¼µÄȱ¿ÚÄ©¶Ë±ê¼Ç·¨(TUNEL)¡¢ÃâÒßÓ¡¼£·¨(Western Blotting)¼ì²âD19¶ÔÈËÈéÏÙ°©Ï¸°ûϵMCF-7ºÍMDA-MB-435Éú³¤µÄÓ°Ïì¼°Ïà¹ØÐźÅͨ·µ°°×µÄ±ä»¯¡£½á¹û D19¶ÔMCF-7¡¢MDA-MB-435µÄ°ëÊýÒÖ֯ō¶È(IC50)·Ö±ðΪ4.01 ¦Ìmol/LºÍ7.32 ¦Ìmol/L;D19¾ßÓÐÓÐЧÓÕµ¼ÈËÈéÏÙ°©Ï¸°ûµòÍöµÄ×÷ÓÃ;Western Blotting½á¹ûÏÔʾD19×÷Óúóϸ°ûÖеĵòÍöµ°°×Èçcaspase 9ÒÔ¼°ÏÂÓεÄЧӦµ°°×PARP¶¼·¢ÉúÁѽ⡣½áÂÛ ´Óϸ°ûˮƽºÍ·Ö×Óˮƽ֤Ã÷ÐÂÐͺ£ÑóÔ´ÐÔÝì»·À໯ºÏÎïD19¾ßÓкÜÇ¿µÄ¿¹ÈéÏÙ°©»îÐÔ£¬ÓпÉÄÜ·¢Õ¹³ÉΪÖÎÁÆÈéÏÙ°©µÈÆäËûʵÌåÖ×ÁöµÄÏȵ¼»¯ºÏÎï¡£ ¡¾¹Ø¼ü´Ê¡¿  º£Ñó¹²Éú΢ÉúÎï;¿¹Ö×Áö;Ýì»·À໯ºÏÎï;ÈËÈéÏÙ°©Ï¸°û;µòÍö Abstract:ObjectiveTo study the antineoplastic activity and mechanism of D19,a novel anthracycline derived from marine commensal microorganisms at both cellular level and molecular level. Methods The inhibitory effects of D19 on growth of breast cancer cell lines were determined by MTT assay. The molecular signaling pathways of apoptosis were measured by terminal deoxynucleotidyl transferase (TDT)-mediated biotinylated deoxyuridine-triphosphate (dUTP)-biotin nick end labeling (TUNEL) staining and western blotting. Results IC50 of D19 on MCF-7 and MDA-MB-435 cell lines were 4.01 ¦Ìmol/L and 7.32 ¦Ìmol/L respectively. TUNEL staining showed that D19 could induce apoptosis in MCF-7 cells. In addition,Western blot detected some apoptosis proteins such as caspase 9 and PARP being cleaved after treatment with D19. Conclusion These results suggested that D19 might be used as a promising chemotherapeutical agent for patients with breast cancer and other solid cancer. Key words:marine commensal microorganism;antineoplastic;anthracycline;human breast cancer cells;apoptosis ³¤ÆÚÒÔÀ´£¬¶ñÐÔÖ×ÁöÒ»Ö±ÑÏÖØÍþв×ÅÈËÀཡ¿µÓëÉúÃü¡£¾ÝÊÀ½çÎÀÉú×é֯ͳ¼Æ£¬È«ÊÀ½çÿÄêÔ¼ÓÐ600ÍòÈ˱»°©Ö¢¶áÈ¥ÉúÃü£¬¹À¼Æµ½2020Ä꽫ÉýÖÁ1 000ÍòÈË[1]¡£ÆäÖÐÈéÏÙ°©ÊÇÅ®ÐÔ×î³£¼ûµÄ¶ñÐÔÖ×ÁöÖ®Ò»£¬¶øÇÒÊÇʵÌåÁöÖÐÓ¦Óû¯ÁÆ×îÓÐЧµÄÖ×ÁöÖ®Ò»¡£Òò´ËѰÕÒÓÐЧµÄ¿¹Ö×Áö»¯ºÏÎï¶ÔÓÚÈéÏÙ°©µÄÖÎÁƾßÓÐÖØÒªµÄÒâÒå¡£Ýì»·À໯ÁÆÒ©ÎïÊÇĿǰÁÙ´²Ó¦Óù㷺µÄ¿¹Ö×ÁöÒ»Ïß»¯ÁÆÒ©ÎÓÈÆäÊÇÈéÏÙ°©»¯ÁÆÖÐ×î³£ÓõÄÒ©Îµ«ÊÇ´ËÀàÒ©ÎïÈÔ´æÔÚ¹ÇËèÒÖÖÆÐÔ¡¢ÐÄÔà¶¾ÐÔÎÊÌ⣬ÒÔ¼°Ö×Áö»¼Õß³¤ÆÚʹÓóöÏֵĶàÄÍÒ©ÏÖÏ󣬴ó´óÏÞÖÆÁËÆä¼ÁÁ¿Ìá¸ßºÍÁÙ´²ÖÎÁÆÐ§¹û[2-4]¡£Òò´Ë£¬ÓбØÒªÑ°ÕÒ¸üºÃµÄͬÀ໯ÁÆÌæ´úÒ©Îï[5]¡£±¾ÎÄ´Ó·Ö×ÓˮƽºÍϸ°ûˮƽ¶Ôº£Ñó΢ÉúÎïÀ´Ô´µÄÝì»·À໯ºÏÎïD19¿¹ÈËÈéÏÙ°©×÷ÓýøÐÐÁËÑо¿£¬Îª¸Ã»¯ºÏÎï×îÖÕ³ÉΪ¿¹Ö×ÁöÒ©ÎïÌṩÀíÂÛÒÀ¾Ý£¬²¢Îª½øÒ»²½¿ª·¢¸ßЧµÍ¶¾µÄ¿¹Ö×ÁöÐÂÐͺòѡҩÎïµì¶¨»ù´¡¡£ 1²ÄÁÏÓëÒ©Îï ÈËÈéÏÙ°©Ï¸°ûϵMDA-MB-435¡¢MCF-7Ϊ±¾ÊµÑéÊÒ±£´æ£¬²¢ÒÑÔÚ±¾ÊµÑéÊÒÒÑ·¢±íµÄÆäËûÑо¿ÏîÄ¿ÖÐʹÓÃ[6]¡£D19ÓÉÖÐɽ´óѧ»¯Ñ§Ó뻯ѧ¹¤³ÌѧԺÁÖÓÀ³É½ÌÊÚÌṩ[7]¡£¸÷ÖÖ»¯ºÏÎïÓɶþ¼×»ùÑÇí¿(DMSO)(Sigma¹«Ë¾)ÖÆ±¸±£´æÄ¸Òº¡£ 2·½·¨ 2.1ϸ°ûÅàÑø ÈËÈéÏÙ°©Ï¸°ûϵMCF-7¡¢MDA-MB-435ÅàÑøÓÚº¬5%(¦Õ)̥ţѪÇå(Hyclone¹«Ë¾)¡¢2 mmol/L L-¹È°±õ£°·¡¢ 0.1 mmol/L·Ç±ØÐè°±»ùËá¡¢ 10 mmol/L Hepes(»º³åÒº)¡¢100 IU/mLÇàÃ¹ËØºÍ100 ¦Ìg/mLÁ´Ã¹ËصÄDMEMÍêÈ«ÅàÑø»ùÖÐ(ÒÔÉÏϸ°ûÅàÑøÏà¹ØÊÔ¼Á¾ùΪInvitrogen/Gibco¹«Ë¾²úÆ·£¬¹º×ÔInvitrogen¹«Ë¾)£¬ÖÃÓÚ37 ¡æ 5%(¦Õ) CO2·õÏäÖзõÓýÅàÑø¡£´«´úʱÓú¬0.02%EDTAµÄ0.05%(¦Õ)ÒÈøÏû»¯£¬ÒÔDMEMÍêÈ«ÅàÑø»ùÖÕÖ¹Ïû»¯¡£ 2.2Ëļ׻ùżµªßòÀ¶(MTT)±ÈɫʵÑé ½«MCF-7ºÍMDA-MB-435ϸ°ûÏû»¯ºó¼ÆÊý£¬°´Ã¿¿×1.0¡Á104¸öϸ°û·Ö±ð½ÓÖÖÖÁ96 ¿×ϸ°ûÅàÑø°åÖУ¬ÖÃÓÚ37 ¡æ 5%CO2·õÏäÖзõÓýÅàÑø¡£24 hºó¸ü»»Îªº¬Å¨¶ÈÒÀ´ÎΪ0¡¢0.001¡¢0.05¡¢0.1¡¢0.5¡¢1¡¢2¡¢3¡¢4 ¦Ìmol/L D19µÄÅàÑø»ù£¬Ã¿¸öŨ¶È¾ùÉè3¸öƽÐи´¿×£¬¼ÌÐøÅàÑø48 hºó£¬ÏÔ΢¾µÏ¹۲ìϸ°ûÐÎ̬¼°Éú³¤µÄ±ä»¯¡£Ëæºóÿ¿×¼ÓÈëÖÊÁ¿Å¨¶ÈΪ5 mg/mL MTT(Genview¹«Ë¾£¬ÓÃ1¡ÁÁ×ËáÑλº³åÒºÈܽ⣬ÖÕÖÊÁ¿Å¨¶È5 mg/mL£¬¹ýÂ˳ý¾ú£¬·Ö×°ºó-20 ¡æ±Ü¹â±£´æ)ÈÜÒº20 ¦ÌL£¬37 ¡æ×÷ÓÃ4 h£¬ÀëÐĺóÆúÉÏÇåÒº£¬¼ÓÈëDMSO 150 ¦ÌL£¬Õñµ´Æ÷Õñµ´10 min³ä·ÖÈܽâ½á¾§£¬ÖÃø±êÒÇÉϲⶨ²¨³¤Îª490 nmϵÄÎü¹â¶ÈAÖµ£¬°´ÒÔϹ«Ê½¼ÆËãÒÖÖÆÂÊ¡£Ï¸°ûÉú³¤ÒÖÖÆÂÊ(%)=(¶ÔÕÕ×鯽¾ùAÖµ-ʵÑé×鯽¾ùAÖµ)/¶ÔÕÕ×鯽¾ùAÖµ¡Á100 %¡£¶ÔÕÕ×é¼´D19Ũ¶ÈΪ0µÄÅàÑø¿×¡£Ê¹ÓðëÊýÒÖ֯ō¶È(IC50)¼ÆËãÈí¼þBliss¡¯s software ¼ÆËãIC50£¬Ó¦ÓÃSPSSÈí¼þÐÐÊý¾Ýͳ¼Æ·ÖÎö¡£ 2.3ÍÑÑõºËÌǺËËáÄ©¶Ë×ªÒÆÃ¸½éµ¼µÄȱ¿ÚÄ©¶Ë±ê¼Ç·¨(TUNEL)Ⱦɫ 
¾­¹ÜÖ®¼Ò¡°Ñ§µÀ»á¡±Ð¡³ÌÐò
  • ɨÂë¼ÓÈë¡°¿¼ÑÐѧϰ±Ê¼ÇȺ¡±
ÍÆ¼öÔĶÁ
¾­¼ÃѧÏà¹ØÎÄÕÂ
±êÇ©ÔÆ
¾­¹ÜÖ®¼Ò¾«²ÊÎÄÕÂÍÆ¼ö